SCHEMBL22001552

SCHEMBL22001552

CC/C(=N\OC(C)=O)c1cc2ccc(Sc3ccccc3)cc2oc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.43
▸ ALDH1A1 P00352 7/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ KDM4E B2RXH2 6/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ MAOB P27338 5/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ CA12 O43570 1/20 0.40
▸ NT5E P21589 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ SLC16A3 O15427 3/20 0.40
▸ HPGD P15428 3/20 0.39
▸ MAPT P10636 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28705252 0.84 KDM4E (0.58) ALDH1A1SMN1; SMN2RAB9AKDM4EMEN1
SCHEMBL28705253 0.84 KDM4E (0.58) ALDH1A1SMN1; SMN2RAB9AKDM4EMEN1
SCHEMBL22001553 0.81 MAOB (0.41) HSD11B1ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL28719031 0.80 ALDH1A1 (0.64) HSD11B1ALDH1A1RAB9AKDM4EKMT2A
SCHEMBL28719029 0.80 ALDH1A1 (0.64) HSD11B1ALDH1A1RAB9AKDM4EKMT2A
SCHEMBL22001255 0.78 ALDH1A1 (0.46) HSD11B1ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL22001252 0.78 MAOB (0.40) HSD11B1ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL28718969 0.75 LMNA (0.63) ALDH1A1SMN1; SMN2RAB9AKDM4EMEN1
SCHEMBL28718971 0.75 LMNA (0.63) ALDH1A1SMN1; SMN2RAB9AKDM4EMEN1
SCHEMBL28718974 0.75 MAOB (0.56) MAOBCA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11142511-B2 Coumarin oxime ester compounds, preparation and use thereof HUBEI GURUN TECHNOLOGY CO., LTD. (CN) 2021-10-12 — — US disclosed
EP-3660008-A1 COUMARIN OXIME ESTER COMPOUND AND PREPARATION AND USE THEREOF Hubei Gurun Technology Co., Ltd (CN) 2020-06-03 — — EP disclosed
US-20200148660-A1 COUMARIN OXIME ESTER COMPOUNDS, PREPARATION AND USE THEREOF HUBEI GURUN TECHNOLOGY CO. LTD (CN) 2020-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148660-A1 COUMARIN OXIME ESTER COMPOUNDS, PREPARATION AND USE THEREOF CBR3, POR, CYP3A4 HSD11B1 2680/4885ALDH1A1 457/4885SMN1; SMN2 4589/4885
US-11142511-B2 Coumarin oxime ester compounds, preparation and use thereof CBR3, POR, CYP3A4 HSD11B1 2680/4885ALDH1A1 457/4885SMN1; SMN2 4589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback